MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-100164-PIP01-21

Scope of the Application

Active Substance(s)

(1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

Condition(s)

Treatment of coronavirus disease 2019 (COVID-19), Prevention of coronavirus disease 2019 (COVID-19)

Pharmaceutical Form(s)

Film coated tablet; Age appropriate oral formulation.

Route(s) of Administration

Oral use

Name / Corporate name of the PIP applicant

Pfizer Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Pfizer Limited submitted to the licensing authority on 05/08/2021 20:09 BST an application for a Paediatric Investigation Plan

The procedure started on 21/09/2021 14:57 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

The agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100164-PIP01-21

Of 23/12/2021 09:51 GMT

On the adopted decision for (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (MHRA-100164-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, Film coated tablet; Age appropriate oral formulation. , Oral use .

This decision is addressed to Pfizer Limited, Ramsgate Road, Sandwich, Kent, United Kingdom, CT139NJ

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of coronavirus disease 2019 (COVID-19); Prevention of coronavirus disease 2019 (COVID-19)

2.2 Indication(s) targeted by the PIP:

Treatment of coronavirus disease 2019 (COVID-19); Prevention of coronavirus disease 2019 (COVID-19)

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film coated tablet; Age appropriate oral formulation

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1(Same for both Treatment and Prevention of coronavirus disease 2019 [COVID-19]) Development of an age-appropriate pharmaceutical form for (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide in combination with ritonavir [PF 07321332 with ritonavir] for the paediatric population from birth to less than 6 years of age .
Non-Clinical Studies	0	Not applicable
Clinical Studies	1	Study 2 (C4671026) (Same for both Treatment and Prevention of coronavirus disease 2019 [COVID-19]) Open label study to evaluate the pharmacokinetics (PK), safety and efficacy of PF 07321332 (with ritonavir) for the treatment of children from birth to less than 18 years of age with coronavirus disease 2019 and at risk for progression to severe COVID-19.
Extrapolation, Modeling & Simulation Studies	4	Study 3 (Same for both Treatment and Prevention of coronavirus disease 2019 [COVID-19]) Population PK modelling and simulation study to simulate multidose administration of PF 07321332 (with ritonavir)

		across in children from birth to less than 18 years of age with COVID-19 to inform dose for paediatric clinical study 2 Study 4 (Same for both Treatment and Prevention of coronavirus disease 2019 [COVID-19]) Population PK modelling to simulate multiple-dose administration of PF-07321332 with ritonavir in children from birth to less than 18 years of age with COVID-19 for the treatment of COVID-19 and in healthy children for the prevention of COVID-19 to select final paediatric dose recommendations by matching exposures in adults. Study 5 (For Treatment of coronavirus disease 2019 [COVID-19]) Extrapolation study of efficacy and safety of PF-07321332 with ritonavir from adults to children from birth to less than 18 years of age with COVID-19 who are at risk for progression to severe COVID-19. Study 6 (For Prevention of coronavirus disease 2019 [COVID-19]) Extrapolation study of efficacy and safety of PF-07321332 with ritonavir from healthy adults to healthy children from birth to less than 18 years of age for the prevention of COVID-19.
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/12/2024
Deferral of one or more studies contained in the paediatric investigation plan:	Yes